The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo.
<h4>Objection</h4>To investigate the safety and treatment response of radioimmunotherapy (RIT) in combination with radiofrequency ablation (RFA) for the treatment of VX2 tumor on rabbit.<h4>Materials and methods</h4>A total of 36 rabbits bearing VX2 tumor on the thigh were ra...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0096539&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850023483785871360 |
|---|---|
| author | Shu-Guang Zheng Hui-Xiong Xu Le-Hang Guo Lin-Na Liu Feng Lu |
| author_facet | Shu-Guang Zheng Hui-Xiong Xu Le-Hang Guo Lin-Na Liu Feng Lu |
| author_sort | Shu-Guang Zheng |
| collection | DOAJ |
| description | <h4>Objection</h4>To investigate the safety and treatment response of radioimmunotherapy (RIT) in combination with radiofrequency ablation (RFA) for the treatment of VX2 tumor on rabbit.<h4>Materials and methods</h4>A total of 36 rabbits bearing VX2 tumor on the thigh were randomly assigned into 3 groups (group I: 1-2 cm; group II: 2-3 cm; group III: 3-4 cm) and 4 subgroups (A: as control, just puncture the tumor using the RFA electrode without power output; B: RFA alone; C: 131I-chTNT intratumoral injection alone; D: RFA+131I-chTNT intratumoral injection 3 days later). The variation of blood assay, weight and survival among different groups and subgroups were used to assess the treatment safety. Ultrasound (US) was used to monitor and assess the tumor response after treatment.<h4>Results</h4>According to the results of the weight and the blood assay among different groups, subgroups, and at two time points (one day before and the 16th day after treatment), no damages to the liver, kidney function and myelosuppression resulting from the treatment were found. No significant differences in survivals among the four subgroups (p = 0.087) were found. In addition, 131I-chTNT did not show significant inhibition effect on VX2 tumor progression according to US measurements.<h4>Conclusion</h4>131I-chTNT intratumoral injection alone or in combination with RFA is relatively safe for rabbit without significant toxicity and shows no significant effect on the survival. The treatment response is not as satisfactory as anticipated. |
| format | Article |
| id | doaj-art-72f854c66c2542cfbec43bc443b2d531 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-72f854c66c2542cfbec43bc443b2d5312025-08-20T03:01:22ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0195e9653910.1371/journal.pone.0096539The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo.Shu-Guang ZhengHui-Xiong XuLe-Hang GuoLin-Na LiuFeng Lu<h4>Objection</h4>To investigate the safety and treatment response of radioimmunotherapy (RIT) in combination with radiofrequency ablation (RFA) for the treatment of VX2 tumor on rabbit.<h4>Materials and methods</h4>A total of 36 rabbits bearing VX2 tumor on the thigh were randomly assigned into 3 groups (group I: 1-2 cm; group II: 2-3 cm; group III: 3-4 cm) and 4 subgroups (A: as control, just puncture the tumor using the RFA electrode without power output; B: RFA alone; C: 131I-chTNT intratumoral injection alone; D: RFA+131I-chTNT intratumoral injection 3 days later). The variation of blood assay, weight and survival among different groups and subgroups were used to assess the treatment safety. Ultrasound (US) was used to monitor and assess the tumor response after treatment.<h4>Results</h4>According to the results of the weight and the blood assay among different groups, subgroups, and at two time points (one day before and the 16th day after treatment), no damages to the liver, kidney function and myelosuppression resulting from the treatment were found. No significant differences in survivals among the four subgroups (p = 0.087) were found. In addition, 131I-chTNT did not show significant inhibition effect on VX2 tumor progression according to US measurements.<h4>Conclusion</h4>131I-chTNT intratumoral injection alone or in combination with RFA is relatively safe for rabbit without significant toxicity and shows no significant effect on the survival. The treatment response is not as satisfactory as anticipated.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0096539&type=printable |
| spellingShingle | Shu-Guang Zheng Hui-Xiong Xu Le-Hang Guo Lin-Na Liu Feng Lu The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo. PLoS ONE |
| title | The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo. |
| title_full | The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo. |
| title_fullStr | The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo. |
| title_full_unstemmed | The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo. |
| title_short | The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo. |
| title_sort | safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor a study in vivo |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0096539&type=printable |
| work_keys_str_mv | AT shuguangzheng thesafetyandtreatmentresponseofcombinationtherapyofradioimmunotherapyandradiofrequencyablationforsolidtumorastudyinvivo AT huixiongxu thesafetyandtreatmentresponseofcombinationtherapyofradioimmunotherapyandradiofrequencyablationforsolidtumorastudyinvivo AT lehangguo thesafetyandtreatmentresponseofcombinationtherapyofradioimmunotherapyandradiofrequencyablationforsolidtumorastudyinvivo AT linnaliu thesafetyandtreatmentresponseofcombinationtherapyofradioimmunotherapyandradiofrequencyablationforsolidtumorastudyinvivo AT fenglu thesafetyandtreatmentresponseofcombinationtherapyofradioimmunotherapyandradiofrequencyablationforsolidtumorastudyinvivo AT shuguangzheng safetyandtreatmentresponseofcombinationtherapyofradioimmunotherapyandradiofrequencyablationforsolidtumorastudyinvivo AT huixiongxu safetyandtreatmentresponseofcombinationtherapyofradioimmunotherapyandradiofrequencyablationforsolidtumorastudyinvivo AT lehangguo safetyandtreatmentresponseofcombinationtherapyofradioimmunotherapyandradiofrequencyablationforsolidtumorastudyinvivo AT linnaliu safetyandtreatmentresponseofcombinationtherapyofradioimmunotherapyandradiofrequencyablationforsolidtumorastudyinvivo AT fenglu safetyandtreatmentresponseofcombinationtherapyofradioimmunotherapyandradiofrequencyablationforsolidtumorastudyinvivo |